基于真实世界的磷酸奥司他韦口服制剂流感暴发期临床应用评价

Evaluation of Clinical Application of Oral Oseltamivir Based on Real-world during the Height of Influenza Outbreak

目的了解流感暴发期磷酸奥司他韦口服制剂在住院真实世界人群中的应用情况及临床安全性,为临床合理应用提供参考。方法采取回顾性、多中心监测方式,收集湖北省6家医院2017年1月1日-2017年4月30日使用磷酸奥司他韦的住院患者,对用药人群特征、用药信息及不良反应(ADR)进行总结分析。结果共收集用药患者1327例,其中3岁以下儿童占比32.71%;用药科室主要分布在儿科、呼吸与危重症医学科、感染科;平均用药天数为3.97 d;不良反应9例(0.68%)。结论磷酸奥司他韦口服制剂临床使用广泛,安全性相对较高,但仍需规范其临床应用,减少或避免ADR发生,保障用药安全。

Objective To observe the clinical application and safety of oral oseltamivir in hospitalized patients in the real-world during the height of an influenza outbreak,and to make recommendations for clinical application.Methods During this multi-center and retrospective research,all the information was collected from patients from six hospitals in Hubei Province who had taken oseltamivir between January 1,2017 and April 30,2017.The data on these patients was analyzed with specific focus on demographic characteristics,medical information and adverse reactions(ADRs).Results A total of 1327 cases were collected,about 32.71% of whom were children under 3.Oral oseltamivir was prescribed mainly by departments of pediatrics,respiratory diseases and infections.The mean time of medication was 3.97 days.Only 9 cases recorded ADRs(0.68%).Conclusion Oral oseltamivir is widely used in clinical practice,and it is relatively safe.However,its clinical application needs to be standardized in order to reduce or prevent ADRs and ensure the safety of drug use.